Substituted heterobicyclic derivatives as negative allosteric modulators of mglu7 receptor

Substituted heterobicyclic derivatives as negative allosteric modulators of mglu7 receptor

The present invention relates to novel compounds of Formula (I), wherein A, m, Q, R1, R2, R3, R4 and R5 are defined as in Formula (I); which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurologica...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: PAPARIN Jean-Laurent, ROCHER Jean-Philippe, STACH Tanja, DUVEY Guillaume, TANG Lam, M?DER Patrick
Format: Patent
Sprache:eng ; heb
Schlagworte:
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator PAPARIN Jean-Laurent
ROCHER Jean-Philippe
STACH Tanja
DUVEY Guillaume
TANG Lam
M?DER Patrick
description The present invention relates to novel compounds of Formula (I), wherein A, m, Q, R1, R2, R3, R4 and R5 are defined as in Formula (I); which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_IL308380A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>IL308380A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_IL308380A3</originalsourceid><addsrcrecordid>eNqFyrEKwjAUheEuDqK-gtwXEAoZ7CqiKLjp5FLS5LQG0ibk3hR8e4O4Ox3-w7esnvfcsTjJAksvCFLonHkb7wxZJDdrcTOYNNOE4RukvQ9cZCFjsNlrCYkp9DQOPu8pwSCWa10teu0Zm9-uqu359DhedoihBUdtMEHa603VjWrqg_oLPnmZOwY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Substituted heterobicyclic derivatives as negative allosteric modulators of mglu7 receptor</title><source>esp@cenet</source><creator>PAPARIN Jean-Laurent ; ROCHER Jean-Philippe ; STACH Tanja ; DUVEY Guillaume ; TANG Lam ; M?DER Patrick</creator><creatorcontrib>PAPARIN Jean-Laurent ; ROCHER Jean-Philippe ; STACH Tanja ; DUVEY Guillaume ; TANG Lam ; M?DER Patrick</creatorcontrib><description>The present invention relates to novel compounds of Formula (I), wherein A, m, Q, R1, R2, R3, R4 and R5 are defined as in Formula (I); which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.</description><language>eng ; heb</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240101&amp;DB=EPODOC&amp;CC=IL&amp;NR=308380A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25542,76516</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20240101&amp;DB=EPODOC&amp;CC=IL&amp;NR=308380A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>PAPARIN Jean-Laurent</creatorcontrib><creatorcontrib>ROCHER Jean-Philippe</creatorcontrib><creatorcontrib>STACH Tanja</creatorcontrib><creatorcontrib>DUVEY Guillaume</creatorcontrib><creatorcontrib>TANG Lam</creatorcontrib><creatorcontrib>M?DER Patrick</creatorcontrib><title>Substituted heterobicyclic derivatives as negative allosteric modulators of mglu7 receptor</title><description>The present invention relates to novel compounds of Formula (I), wherein A, m, Q, R1, R2, R3, R4 and R5 are defined as in Formula (I); which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqFyrEKwjAUheEuDqK-gtwXEAoZ7CqiKLjp5FLS5LQG0ibk3hR8e4O4Ox3-w7esnvfcsTjJAksvCFLonHkb7wxZJDdrcTOYNNOE4RukvQ9cZCFjsNlrCYkp9DQOPu8pwSCWa10teu0Zm9-uqu359DhedoihBUdtMEHa603VjWrqg_oLPnmZOwY</recordid><startdate>20240101</startdate><enddate>20240101</enddate><creator>PAPARIN Jean-Laurent</creator><creator>ROCHER Jean-Philippe</creator><creator>STACH Tanja</creator><creator>DUVEY Guillaume</creator><creator>TANG Lam</creator><creator>M?DER Patrick</creator><scope>EVB</scope></search><sort><creationdate>20240101</creationdate><title>Substituted heterobicyclic derivatives as negative allosteric modulators of mglu7 receptor</title><author>PAPARIN Jean-Laurent ; ROCHER Jean-Philippe ; STACH Tanja ; DUVEY Guillaume ; TANG Lam ; M?DER Patrick</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_IL308380A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; heb</language><creationdate>2024</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>PAPARIN Jean-Laurent</creatorcontrib><creatorcontrib>ROCHER Jean-Philippe</creatorcontrib><creatorcontrib>STACH Tanja</creatorcontrib><creatorcontrib>DUVEY Guillaume</creatorcontrib><creatorcontrib>TANG Lam</creatorcontrib><creatorcontrib>M?DER Patrick</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>PAPARIN Jean-Laurent</au><au>ROCHER Jean-Philippe</au><au>STACH Tanja</au><au>DUVEY Guillaume</au><au>TANG Lam</au><au>M?DER Patrick</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Substituted heterobicyclic derivatives as negative allosteric modulators of mglu7 receptor</title><date>2024-01-01</date><risdate>2024</risdate><abstract>The present invention relates to novel compounds of Formula (I), wherein A, m, Q, R1, R2, R3, R4 and R5 are defined as in Formula (I); which are negative allosteric modulators of the metabotropic glutamate receptor subtype 7 (mGlu7) and which are useful for the treatment or prevention of neurological, ear and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGlu7 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and such compositions, and to the use of such compounds for the prevention or treatment of neurological, ear and psychiatric disorders and diseases in which mGlu7 is involved.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng ; heb
recordid cdi_epo_espacenet_IL308380A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Substituted heterobicyclic derivatives as negative allosteric modulators of mglu7 receptor
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T09%3A05%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=PAPARIN%20Jean-Laurent&rft.date=2024-01-01&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EIL308380A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true